Drugs / RSN0402
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06482190 | Jul → Dec 2024 | idiopathic pulmonary fibrosis, pulmonary fibrosis | Shenzhen Resproly Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSN0402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06482190 ↗ |
| Route | Inhaled | “via inhalation using a dry powder inhalant.” NCT06482190 ↗ |